Agency Information Collection Activities: Proposed Collection; Comment Request, 10730-10732 [2018-04893]
Download as PDF
10730
Federal Register / Vol. 83, No. 48 / Monday, March 12, 2018 / Notices
terms. CDC reviews potential candidates
for the BSC, NCIPC membership each
year, and provides a slate of nominees
for consideration to the Secretary of
HHS for final selection. HHS notifies
selected candidates of their
appointment near the start of the term
in August 31, 2019, or as soon as the
HHS selection process is completed.
Note that the need for different expertise
varies from year to year and a candidate
who is not selected in one year may be
reconsidered in a subsequent year.
Nominees must be U.S. citizens, and
cannot be full-time employees of the
U.S. Government. Candidates should
submit the following items:
D Current curriculum vitae, including
complete contact information
(telephone numbers, mailing address,
email address)
D At least one letter of
recommendation from person(s) not
employed by the U.S. Department of
Health and Human Services.
(Candidates may submit letter(s) from
current HHS employees if they wish,
but at least one letter must be submitted
by a person not employed by an HHS
agency (e.g., CDC, NIH, FDA, etc.).
D Nominations may be submitted by
the candidate him- or herself, or by the
person/organization recommending the
candidate.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both CDC and
the Agency for Toxic Substances and
Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2018–04927 Filed 3–9–18; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
amozie on DSK30RV082PROD with NOTICES
[Docket No. CDC–2015–0049]
Notice of Availability of the Final
Revised Environmental Assessment
and a Finding of No Significant Impact
for HHS/CDC Lawrenceville Campus
Proposed Improvements 2015–2025,
Lawrenceville, Georgia
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of Availability of the
Final Revised Environmental
AGENCY:
VerDate Sep<11>2014
18:12 Mar 09, 2018
Jkt 244001
Assessment and a Finding of No
Significant Impact.
The Centers for Disease
Control and Prevention (CDC), within
the Department of Health and Human
Services (HHS) announces the
availability of the Final Revised
Environmental Assessment (EA) and a
Finding of No Significant Impact
(FONSI) for the CDC Lawrenceville
Campus Proposed Improvements 2015–
2025.
FOR FURTHER INFORMATION CONTACT:
Stephen Klim, RA, Office of Safety,
Security, and Asset Management,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
K96, Atlanta, Georgia 30329, Telephone:
(770)488–8009.
SUPPLEMENTARY INFORMATION: On
February 16, 2016 CDC published a
Notice of Availability for the Final
Environmental Assessment (2016 Final
EA) and FONSI for the HHS/CDC’s
Lawrenceville Campus Proposed
Improvements 2015–2025 (81 FR 7800).
The 2016 Final EA assessed the
potential impacts associated with the
undertaking of proposed improvements
on the HHS/CDC’s Lawrenceville
Campus located at 602 Webb Gin House
Road in Lawrenceville, Georgia. The
proposed improvements include: (1)
Building demolition; (2) new building
construction, including an
approximately 12,000 gross square feet
(gsf) Science Support Building, a new
Transshipping and Receiving Area at
approximately 2,500 gsf and two new
small Office Support Buildings at 8,000
gsf and 6,000 gsf; (3) expansion and
relocation of parking on campus; and (4)
the creation of an additional point of
access to the campus.
Since the completion of the 2016
Final EA and FONSI, HHS/CDC
proposed changes to the Proposed
Action to include the installation of a
photovoltaic system. HHS/CDC revised
the EA in order to evaluate the potential
environmental impacts association with
the new photovoltaic system. On
September 22, 2017 HHS/CDC
published a NOA in the Federal
Register announcing the availability of
the Revised EA and requested public
comment. The comment period ended
on October 23, 2017.
CDC assessed the potential impacts of
the proposed improvements on the
natural and human environment and
determined that the proposed action
would not result in significant adverse
impacts. Based on the results of the
Final Revised EA, CDC has issued a
FONSI indicating the proposed action
will not have a significant impact on the
environment. The Build Alternative will
SUMMARY:
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
be undertaken in accordance with the
best management practices (BMPs),
minimization and mitigation measures
as presented in the Final EA and FONSI.
Copies of the FONSI and/or Final
Revised EA are available by contacting
Stephen Klim (please see FOR FURTHER
INFORMATION CONTACT).
Dated: March 6, 2018.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2018–04902 Filed 3–9–18; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifiers: CMS–10394, CMS–
10544, CMS–10008, CMS–855I, and CMS–
10545]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, HHS.
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995 (the
PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information (including each proposed
extension or reinstatement of an existing
collection of information) and to allow
60 days for public comment on the
proposed action. Interested persons are
invited to send comments regarding our
burden estimates or any other aspect of
this collection of information, including
the necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions,
the accuracy of the estimated burden,
ways to enhance the quality, utility, and
clarity of the information to be
collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
May 11, 2018.
ADDRESSES: When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
SUMMARY:
E:\FR\FM\12MRN1.SGM
12MRN1
Federal Register / Vol. 83, No. 48 / Monday, March 12, 2018 / Notices
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number lll, Room C4–26–
05, 7500 Security Boulevard, Baltimore,
Maryland 21244–1850.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, you may make your request
using one of following:
1. Access CMS’ website address at
https://www.cms.hhs.gov/Paperwork
ReductionActof1995.
2. Email your request, including your
address, phone number, OMB number,
and CMS document identifier, to
Paperwork@cms.hhs.gov.
3. Call the Reports Clearance Office at
(410) 786–1326.
FOR FURTHER INFORMATION CONTACT:
William Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION:
amozie on DSK30RV082PROD with NOTICES
Contents
This notice sets out a summary of the
use and burden associated with the
following information collections. More
detailed information can be found in
each collection’s supporting statement
and associated materials (see
ADDRESSES).
CMS–10394 Application To Be
Qualified Entity To Receive Medicare
Data for Performance Measurement
CMS–10544 Good Cause Processes
CMS–10008 Eligibility of Drugs,
Biologicals, and Radiopharmaceutical
Agents for Transitional Pass-Through
Status Under the Hospital
CMS–855i Medicare Enrollment
Application for Physician and NonPhysician Practitioners
CMS–10545 Outcome and Assessment
Information Set (OASIS) OASIS–C2/
ICD–10
Under the PRA (44 U.S.C. 3501–
3520), federal agencies must obtain
approval from the Office of Management
and Budget (OMB) for each collection of
information they conduct or sponsor.
The term ‘‘collection of information’’ is
defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
VerDate Sep<11>2014
18:12 Mar 09, 2018
Jkt 244001
Section 3506(c)(2)(A) of the PRA
requires federal agencies to publish a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, before
submitting the collection to OMB for
approval. To comply with this
requirement, CMS is publishing this
notice.
Information Collection
1. Type of Information Collection
Request: Extension of a currently
approved collection; Title of
Information Collection: Application to
be Qualified Entity to Receive Medicare
Data for Performance Measurement;
Use: The Patient Protection and
Affordable Care Act (ACA) was enacted
on March 23, 2010 (Pub. L. 111–148).
ACA amends section 1874 of the Social
Security Act by adding a new
subsection (e) to make standardized
extracts of Medicare claims data under
Parts A, B, and D available to qualified
entities to evaluate the performance of
providers of services and suppliers. This
is the application needed to determine
an organization’s eligibility as a
qualified entity. To implement the
requirements outlined in the legislation,
CMS established the Qualified Entity
Certification Program (QECP) to
evaluate an organization’s eligibility
across three areas: Organizational and
governance capabilities, addition of
claims data from other sources (as
required in the statute), and data
privacy and security. This collection
covers the application through which
organizations provide information to
CMS to determine whether they will be
approved as a qualified entity. Form
Number: CMS–10394 (OMB control
number: 0938–1144); Frequency:
Reporting—Yearly; Affected Public:
Private Sector (State, Local, or Tribal
Governments, Business or other forprofits, Not-for-Profit Institutions);
Number of Respondents: 30; Total
Annual Responses: 10; Total Annual
Hours: 5,000. (For policy questions
regarding this collection contact Kari
Gaare at 410–786–8612.)
2. Type of Information Collection
Request: Extension of a currently
approved collection; Title of
Information Collection: Good Cause
Processes; Use: Section 1851(g)(3)(B)(i)
of the Act provides that MA
organizations may terminate the
enrollment of individuals who fail to
pay basic and supplemental premiums
after a grace period established by the
plan. Section 1860D–1(b)(1)(B)(v) of the
Act generally directs us to establish
rules related to enrollment, dis-
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
10731
enrollment, and termination for Part D
plan sponsors that are similar to those
established for MA organizations under
section 1851 of the Act. Consistent with
these sections of the Act, subpart B in
each of the Parts C and D regulations
sets forth requirements with respect to
involuntary dis-enrollment procedures
at 42 CFR 422.74 and 423.44,
respectively. In addition, section
1876(c)(3)(B) establishes that
individuals may be dis-enrolled from
coverage as specified in regulations.
Thus, current regulations at 42 CFR
417.460 specify that a cost plan,
specifically a Health Maintenance
Organization (HMO) or competitive
medical plan (CMP), may dis-enroll a
member who fails to pay premiums or
other charges imposed by the plan for
deductible and coinsurance amounts.
Within these regulatory provisions,
individuals dis-enrolled for
nonpayment of premiums are afforded a
grace period in which to request
reinstatement. As part of the
reinstatement request process, they
must demonstrate good cause for failure
to pay within the initial grace period
that led to their involuntary disenrollment and pay all overdue
premiums within three calendar months
after the dis-enrollment date. Form
Number: CMS–10544 (OMB control
number: 0938–1271); Frequency:
Reporting—Monthly; Affected Public:
Private Sector (Business or other forprofit institutions); Number of
Respondents: 10,008; Total Annual
Responses: 10,008; Total Annual Hours:
6,665. (For policy questions regarding
this collection contact Carla Patterson at
410–786–1000).
3. Type of Information Collection
Request: Reinstatement with a change of
a previously approved collection; Title
of Information Collection: Eligibility of
Drugs, Biologicals, and
Radiopharmaceutical Agents for
Transitional Pass-Through Status under
the Hospital; Use: Section 1833(t)(6) of
the Act provides for temporary
additional payments or ‘‘transitional
pass-through payments’’ for certain
drugs and biological agents. As
originally enacted by the Balanced
Budget Refinement Act (BBRA), this
provision required the Secretary to
make additional payments to hospitals
for current orphan drugs, as designated
under section 526 of the Federal Food,
Drug, and Cosmetic Act (Pub. L. 107–
186); current drugs and biological agents
and brachytherapy used for the
treatment of cancer; and current
radiopharmaceutical drugs and
biological products. For those drugs and
biological agents referred to as
E:\FR\FM\12MRN1.SGM
12MRN1
amozie on DSK30RV082PROD with NOTICES
10732
Federal Register / Vol. 83, No. 48 / Monday, March 12, 2018 / Notices
‘‘current,’’ the transitional pass-through
payment began on the first date the
hospital OPPS was implemented (before
enactment of Benefits Improvement and
Protections Act (BIPA) (Pub. L. 106–
554), on December 21, 2000).
Transitional pass-through payments are
also required for certain ‘‘new’’ drugs,
devices and biological agents that were
not being paid for as a hospital
outpatient department (OPD) service as
of December 31, 1996, and whose cost
is ‘‘not insignificant’’ in relation to the
outpatient perspective payment system
(OPPS) payment for the procedures or
services associated with the new drug,
device, or biological. Under the statute,
transitional pass-through payments can
be made for at least 2 years but not more
than 3 years. We have qualified
thousands for transitional pass-through
payments through our application
process. However, to keep pace with
emerging new technologies and make
them accessible to Medicare
beneficiaries in a timely manner as the
law intended, it is necessary that we
continue to collect appropriate
information from interested parties such
as hospitals and pharmaceutical
companies that bring to our attention
specific new drugs, biologicals and
radiopharmaceuticals to be evaluated
for transitional pass-through status.
Form Number: CMS–10008 (OMB
control number: 0938–0802); Frequency:
Yearly; Affected Public: Private sector
(Business or other for-profit
institutions); Number of Respondents:
30; Total Annual Responses: 30; Total
Annual Hours: 480. (For policy
questions regarding this collection
contact Raymond Bulls at 410–786–
7267).
4. Type of Information Collection
Request: New collection (Request for
new OMB control number); Title of
Information Collection: Medicare
Enrollment Application for Physician
and Non-Physician Practitioners; Use:
The application is used by Medicare
contractors to collect data to ensure that
the applicant has the necessary
credentials to provide the health care
services for which they intend to bill
Medicare, including information that
allows the Medicare contractor to
correctly price, process and pay the
applicant’s claims. This application
collects information to ensure that only
legitimate physicians, non-physician
practitioners, and other eligible
professionals are enrolled in the
Medicare program. It is meant to be the
first line defense to protect our
beneficiaries from illegitimate providers
and to protect the Medicare Trust Fund
against fraud. It also gathers information
VerDate Sep<11>2014
18:12 Mar 09, 2018
Jkt 244001
that allows Medicare contractors to
ensure that the provider/supplier is not
sanctioned from the Medicare and/or
Medicaid program(s), or debarred,
suspended or excluded from any other
Federal agency or program. Form
Number: CMS–855I (OMB control
number: 0938—NEW); Frequency: On
Occasion; Affected Public: State, Local,
or Tribal Governments, Private Sector
(not-for-profit institutions); Number of
Respondents: 513,872; Total Annual
Responses: 1,370,078; Total Annual
Hours: 1,000,167. (For policy questions
regarding this collection contact
Kimberly McPhillips at 410–786–5374).
5. Type of Information Collection
Request: Revision of a currently
approved collection; Title of
Information Collection: Outcome and
Assessment Information Set (OASIS)
OASIS–C2/ICD–10; Use: This request is
for OMB approval to modify the
Outcome and Assessment Information
Set (OASIS) that home health agencies
(HHAs) are required to collect in order
to participate in the Medicare program.
The current version of the OASIS,
OASIS–C2 (0938–1279) data item set
was approved by the Office of
Management and Budget (OMB) on
December 9, 2016 and implemented on
January 1, 2017. We are seeking OMB
approval for the proposed revised
OASIS item set, referred to hereafter as
OASIS–D, scheduled for
implementation on January 1, 2019. The
OASIS D is being modified to: Include
changes pursuant to the Improving
Medicare Post-Acute Care
Transformation Act of 2014 (the
IMPACT Act); accommodate data
element removals to reduce burden; and
improve formatting throughout the
document. Form Number: CMS–10545
(OMB control number: 0938–1279);
Frequency: Occasionally; Affected
Public: Private Sector (Business or other
for-profit and Not-for-profit
institutions); Number of Respondents:
12,149; Total Annual Responses:
18,161,942; Total Annual Hours:
9,943,141. (For policy questions
regarding this collection contact Joan
Proctor at 410–786–0949.)
Dated: March 7, 2018.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2018–04893 Filed 3–9–18; 8:45 am]
BILLING CODE 4120–01–P
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–D–0626]
Proprietary Names for New Animal
Drugs; Draft Guidance for Industry;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a draft
guidance for industry #240 entitled
‘‘Proprietary Names for New Animal
Drugs.’’ This draft guidance provides
recommendations to help new animal
drug sponsors develop proprietary
names for new animal drugs that do not
contribute to medication errors,
negatively impact safe use of the drug,
or misbrand the drug. This draft
guidance proposes a framework for
evaluating proposed proprietary names
before submitting them for review by
the Center for Veterinary Medicine
(CVM or we). It also explains how new
animal drug sponsors can request that
CVM evaluate a proposed proprietary
name.
DATES: Submit either electronic or
written comments on the draft guidance
by May 11, 2018 to ensure that the
Agency considers your comment on this
draft guidance before it begins work on
the final version of the guidance.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
E:\FR\FM\12MRN1.SGM
12MRN1
Agencies
[Federal Register Volume 83, Number 48 (Monday, March 12, 2018)]
[Notices]
[Pages 10730-10732]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-04893]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[Document Identifiers: CMS-10394, CMS-10544, CMS-10008, CMS-855I, and
CMS-10545]
Agency Information Collection Activities: Proposed Collection;
Comment Request
AGENCY: Centers for Medicare & Medicaid Services, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Medicare & Medicaid Services (CMS) is
announcing an opportunity for the public to comment on CMS' intention
to collect information from the public. Under the Paperwork Reduction
Act of 1995 (the PRA), federal agencies are required to publish notice
in the Federal Register concerning each proposed collection of
information (including each proposed extension or reinstatement of an
existing collection of information) and to allow 60 days for public
comment on the proposed action. Interested persons are invited to send
comments regarding our burden estimates or any other aspect of this
collection of information, including the necessity and utility of the
proposed information collection for the proper performance of the
agency's functions, the accuracy of the estimated burden, ways to
enhance the quality, utility, and clarity of the information to be
collected, and the use of automated collection techniques or other
forms of information technology to minimize the information collection
burden.
DATES: Comments must be received by May 11, 2018.
ADDRESSES: When commenting, please reference the document identifier or
OMB control number. To be assured consideration, comments and
recommendations must be submitted in any one of the following ways:
[[Page 10731]]
1. Electronically. You may send your comments electronically to
https://www.regulations.gov. Follow the instructions for ``Comment or
Submission'' or ``More Search Options'' to find the information
collection document(s) that are accepting comments.
2. By regular mail. You may mail written comments to the following
address: CMS, Office of Strategic Operations and Regulatory Affairs,
Division of Regulations Development, Attention: Document Identifier/OMB
Control Number ___, Room C4-26-05, 7500 Security Boulevard, Baltimore,
Maryland 21244-1850.
To obtain copies of a supporting statement and any related forms
for the proposed collection(s) summarized in this notice, you may make
your request using one of following:
1. Access CMS' website address at https://www.cms.hhs.gov/PaperworkReductionActof1995.
2. Email your request, including your address, phone number, OMB
number, and CMS document identifier, to [email protected].
3. Call the Reports Clearance Office at (410) 786-1326.
FOR FURTHER INFORMATION CONTACT: William Parham at (410) 786-4669.
SUPPLEMENTARY INFORMATION:
Contents
This notice sets out a summary of the use and burden associated
with the following information collections. More detailed information
can be found in each collection's supporting statement and associated
materials (see ADDRESSES).
CMS-10394 Application To Be Qualified Entity To Receive Medicare Data
for Performance Measurement
CMS-10544 Good Cause Processes
CMS-10008 Eligibility of Drugs, Biologicals, and Radiopharmaceutical
Agents for Transitional Pass-Through Status Under the Hospital
CMS-855i Medicare Enrollment Application for Physician and Non-
Physician Practitioners
CMS-10545 Outcome and Assessment Information Set (OASIS) OASIS-C2/ICD-
10
Under the PRA (44 U.S.C. 3501-3520), federal agencies must obtain
approval from the Office of Management and Budget (OMB) for each
collection of information they conduct or sponsor. The term
``collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA requires federal agencies
to publish a 60-day notice in the Federal Register concerning each
proposed collection of information, including each proposed extension
or reinstatement of an existing collection of information, before
submitting the collection to OMB for approval. To comply with this
requirement, CMS is publishing this notice.
Information Collection
1. Type of Information Collection Request: Extension of a currently
approved collection; Title of Information Collection: Application to be
Qualified Entity to Receive Medicare Data for Performance Measurement;
Use: The Patient Protection and Affordable Care Act (ACA) was enacted
on March 23, 2010 (Pub. L. 111-148). ACA amends section 1874 of the
Social Security Act by adding a new subsection (e) to make standardized
extracts of Medicare claims data under Parts A, B, and D available to
qualified entities to evaluate the performance of providers of services
and suppliers. This is the application needed to determine an
organization's eligibility as a qualified entity. To implement the
requirements outlined in the legislation, CMS established the Qualified
Entity Certification Program (QECP) to evaluate an organization's
eligibility across three areas: Organizational and governance
capabilities, addition of claims data from other sources (as required
in the statute), and data privacy and security. This collection covers
the application through which organizations provide information to CMS
to determine whether they will be approved as a qualified entity. Form
Number: CMS-10394 (OMB control number: 0938-1144); Frequency:
Reporting--Yearly; Affected Public: Private Sector (State, Local, or
Tribal Governments, Business or other for-profits, Not-for-Profit
Institutions); Number of Respondents: 30; Total Annual Responses: 10;
Total Annual Hours: 5,000. (For policy questions regarding this
collection contact Kari Gaare at 410-786-8612.)
2. Type of Information Collection Request: Extension of a currently
approved collection; Title of Information Collection: Good Cause
Processes; Use: Section 1851(g)(3)(B)(i) of the Act provides that MA
organizations may terminate the enrollment of individuals who fail to
pay basic and supplemental premiums after a grace period established by
the plan. Section 1860D-1(b)(1)(B)(v) of the Act generally directs us
to establish rules related to enrollment, dis-enrollment, and
termination for Part D plan sponsors that are similar to those
established for MA organizations under section 1851 of the Act.
Consistent with these sections of the Act, subpart B in each of the
Parts C and D regulations sets forth requirements with respect to
involuntary dis-enrollment procedures at 42 CFR 422.74 and 423.44,
respectively. In addition, section 1876(c)(3)(B) establishes that
individuals may be dis-enrolled from coverage as specified in
regulations. Thus, current regulations at 42 CFR 417.460 specify that a
cost plan, specifically a Health Maintenance Organization (HMO) or
competitive medical plan (CMP), may dis-enroll a member who fails to
pay premiums or other charges imposed by the plan for deductible and
coinsurance amounts. Within these regulatory provisions, individuals
dis-enrolled for nonpayment of premiums are afforded a grace period in
which to request reinstatement. As part of the reinstatement request
process, they must demonstrate good cause for failure to pay within the
initial grace period that led to their involuntary dis-enrollment and
pay all overdue premiums within three calendar months after the dis-
enrollment date. Form Number: CMS-10544 (OMB control number: 0938-
1271); Frequency: Reporting--Monthly; Affected Public: Private Sector
(Business or other for-profit institutions); Number of Respondents:
10,008; Total Annual Responses: 10,008; Total Annual Hours: 6,665. (For
policy questions regarding this collection contact Carla Patterson at
410-786-1000).
3. Type of Information Collection Request: Reinstatement with a
change of a previously approved collection; Title of Information
Collection: Eligibility of Drugs, Biologicals, and Radiopharmaceutical
Agents for Transitional Pass-Through Status under the Hospital; Use:
Section 1833(t)(6) of the Act provides for temporary additional
payments or ``transitional pass-through payments'' for certain drugs
and biological agents. As originally enacted by the Balanced Budget
Refinement Act (BBRA), this provision required the Secretary to make
additional payments to hospitals for current orphan drugs, as
designated under section 526 of the Federal Food, Drug, and Cosmetic
Act (Pub. L. 107-186); current drugs and biological agents and
brachytherapy used for the treatment of cancer; and current
radiopharmaceutical drugs and biological products. For those drugs and
biological agents referred to as
[[Page 10732]]
``current,'' the transitional pass-through payment began on the first
date the hospital OPPS was implemented (before enactment of Benefits
Improvement and Protections Act (BIPA) (Pub. L. 106-554), on December
21, 2000). Transitional pass-through payments are also required for
certain ``new'' drugs, devices and biological agents that were not
being paid for as a hospital outpatient department (OPD) service as of
December 31, 1996, and whose cost is ``not insignificant'' in relation
to the outpatient perspective payment system (OPPS) payment for the
procedures or services associated with the new drug, device, or
biological. Under the statute, transitional pass-through payments can
be made for at least 2 years but not more than 3 years. We have
qualified thousands for transitional pass-through payments through our
application process. However, to keep pace with emerging new
technologies and make them accessible to Medicare beneficiaries in a
timely manner as the law intended, it is necessary that we continue to
collect appropriate information from interested parties such as
hospitals and pharmaceutical companies that bring to our attention
specific new drugs, biologicals and radiopharmaceuticals to be
evaluated for transitional pass-through status. Form Number: CMS-10008
(OMB control number: 0938-0802); Frequency: Yearly; Affected Public:
Private sector (Business or other for-profit institutions); Number of
Respondents: 30; Total Annual Responses: 30; Total Annual Hours: 480.
(For policy questions regarding this collection contact Raymond Bulls
at 410-786-7267).
4. Type of Information Collection Request: New collection (Request
for new OMB control number); Title of Information Collection: Medicare
Enrollment Application for Physician and Non-Physician Practitioners;
Use: The application is used by Medicare contractors to collect data to
ensure that the applicant has the necessary credentials to provide the
health care services for which they intend to bill Medicare, including
information that allows the Medicare contractor to correctly price,
process and pay the applicant's claims. This application collects
information to ensure that only legitimate physicians, non-physician
practitioners, and other eligible professionals are enrolled in the
Medicare program. It is meant to be the first line defense to protect
our beneficiaries from illegitimate providers and to protect the
Medicare Trust Fund against fraud. It also gathers information that
allows Medicare contractors to ensure that the provider/supplier is not
sanctioned from the Medicare and/or Medicaid program(s), or debarred,
suspended or excluded from any other Federal agency or program. Form
Number: CMS-855I (OMB control number: 0938--NEW); Frequency: On
Occasion; Affected Public: State, Local, or Tribal Governments, Private
Sector (not-for-profit institutions); Number of Respondents: 513,872;
Total Annual Responses: 1,370,078; Total Annual Hours: 1,000,167. (For
policy questions regarding this collection contact Kimberly McPhillips
at 410-786-5374).
5. Type of Information Collection Request: Revision of a currently
approved collection; Title of Information Collection: Outcome and
Assessment Information Set (OASIS) OASIS-C2/ICD-10; Use: This request
is for OMB approval to modify the Outcome and Assessment Information
Set (OASIS) that home health agencies (HHAs) are required to collect in
order to participate in the Medicare program. The current version of
the OASIS, OASIS-C2 (0938-1279) data item set was approved by the
Office of Management and Budget (OMB) on December 9, 2016 and
implemented on January 1, 2017. We are seeking OMB approval for the
proposed revised OASIS item set, referred to hereafter as OASIS-D,
scheduled for implementation on January 1, 2019. The OASIS D is being
modified to: Include changes pursuant to the Improving Medicare Post-
Acute Care Transformation Act of 2014 (the IMPACT Act); accommodate
data element removals to reduce burden; and improve formatting
throughout the document. Form Number: CMS-10545 (OMB control number:
0938-1279); Frequency: Occasionally; Affected Public: Private Sector
(Business or other for-profit and Not-for-profit institutions); Number
of Respondents: 12,149; Total Annual Responses: 18,161,942; Total
Annual Hours: 9,943,141. (For policy questions regarding this
collection contact Joan Proctor at 410-786-0949.)
Dated: March 7, 2018.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office of Strategic Operations and
Regulatory Affairs.
[FR Doc. 2018-04893 Filed 3-9-18; 8:45 am]
BILLING CODE 4120-01-P